Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 16, 2020

SELL
$17.41 - $19.89 $2.18 Million - $2.49 Million
-125,000 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$14.43 - $19.16 $360,750 - $479,000
-25,000 Reduced 16.67%
125,000 $2.23 Million
Q1 2020

May 15, 2020

SELL
$11.67 - $22.53 $875,250 - $1.69 Million
-75,000 Reduced 33.33%
150,000 $2.43 Million
Q4 2019

Feb 14, 2020

SELL
$16.33 - $21.37 $4.49 Million - $5.88 Million
-275,000 Reduced 55.0%
225,000 $4.05 Million
Q3 2019

Nov 14, 2019

SELL
$16.3 - $23.37 $8.15 Million - $11.7 Million
-500,000 Reduced 50.0%
500,000 $10.1 Million
Q2 2019

Aug 14, 2019

SELL
$13.1 - $22.1 $3.28 Million - $5.53 Million
-250,000 Reduced 20.0%
1,000,000 $22.1 Million
Q1 2019

May 15, 2019

BUY
$8.38 - $15.5 $4.61 Million - $8.53 Million
550,000 Added 78.57%
1,250,000 $17.1 Million
Q4 2018

Feb 14, 2019

BUY
$8.65 - $16.28 $6.06 Million - $11.4 Million
700,000 New
700,000 $6.34 Million

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $60.6M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.